Table of Content

1 INTRODUCTION 
    1.1 OBJECTIVES OF THE STUDY 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY 
    1.4 LIMITATIONS 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY 
    2.1 RESEARCH APPROACH 
           2.1.1  SECONDARY SOURCES
                    2.1.1.1 KEY DATA FROM SECONDARY SOURCES
           2.1.2 PRIMARY SOURCES
                    2.1.2.1 KEY DATA FROM PRIMARY SOURCES
                    2.1.2.2 BREAKDOWN OF PRIMARIES
                    2.1.2.3 KEY INDUSTRY INSIGHTS
    2.2 MARKET SIZE ESTIMATION 
           2.2.1  LEUKAPHERESIS MARKET
           2.2.1  LEUKOPAKS MARKET
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION  
    2.4 MARKET SHARE ESTIMATION 
    2.5 ASSUMPTIONS FOR THE STUDY 
    2.6 RISK ASSESSMENT 
    2.7 LIMITATIONS 
    2.8 RECESSION IMPACT ANALYSIS 
3 EXECUTIVE SUMMARY 
4 PREMIUM INSIGHTS 
    4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW 
    4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY 
    4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX 
    4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX 
    4.5 LEUKOPAKS MARKET: OVERVIEW 
    4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY 
    4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX 
    4.8 LEUKOPAKS MARKET: REGIONAL MIX 
5 MARKET OVERVIEW 
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
           5.2.2 RESTRAINTS
           5.2.3 OPPORTUNITIES
           5.2.4 CHALLENGES
    5.3 INDUSTRY INSIGHTS 
    5.4 INDUSTRY TRENDS 
    5.5 VALUE CHAIN ANALYSIS 
    5.6 TECHNOLOGY ANALYSIS 
    5.7 PORTER'S FIVE FORCE ANALYSIS 
    5.8 REGULATORY LANDSCAPE  
           5.8.1 REGULATORY ANALYSIS (LEUKAPHERESIS MARKET)
           5.8.2 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
           5.8.3 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATION 
    5.9 PATENT ANALYSIS (LEUKAPHERESIS MARKET) 
    5.10 PATENT ANALYSIS (LEUKOPAKS MARKET) 
    5.11 PRICING ANALYSIS (LEUKOPAKS MARKET) 
           5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE
           5.11.2 AVERAGE SELLING PRICE TREND OF LEUKOPAKS, BY REGION
    5.12 LEUKAPHERESIS MARKET VENDORS: MAJOR CUSTOMERS 
    5.13 KEY CONFERENCES & EVENTS DURING 2023-2024 
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS & BUYING PROCESS
           5.14.2 BUYING CRITERIA
    5.15 ECOSYSTEM ANALYSIS  
    5.16 CASE STUDY ANALYSIS  
    5.17 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS  
    5.18 ADJACENT MARKET ANALYSIS 
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 
    6.1 INTRODUCTION 
    6.2 LEUKAPHERESIS DISPOSABLES 
    6.3 LEUKAPHERESIS DEVICES 
           6.3.1 CENTRIFUGAL DEVICES
           6.3.2 MEMBRANE SEPARATORS
7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 
    7.1 INTRODUCTION 
    7.2 RESEARCH APPLICATIONS 
    7.3 THERAPEUTIC APPLICATIONS 
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION) 
    8.1 INTRODUCTION 
    8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 
    8.3 ACADEMIC & RESEARCH INSTITUTES 
    8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
    8.5 HOSPITALS & TRANSFUSION CENTERS 
9 LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION) 
    9.1 INTRODUCTION 
    9.2 MOBILIZED LEUKOPAKS 
    9.3 NON-MOBILIZED LEUKOPAKS 
    9.4 DISEASED LEUKOPAKS 
    9.5 ISOLATED PBMCS 
10 LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION) 
     10.1 INTRODUCTION 
     10.2 ACUTE LYMPHOCYTIC LEUKEMIA 
     10.3 MULTIPLE MYELOMA 
     10.4 NON-HODGKIN’S LYMPHOMA 
     10.5 CHRONIC LYMPHOCYTIC LEUKEMIA 
     10.6 PANCREATIC CANCER 
     10.7 HEPATOCELLULAR CARCINOMA 
     10.8 OTHER INDICATIONS 
11 LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION) 
     11.1 INTRODUCTION 
     11.2 ACADEMIC & RESEARCH INSTITUTES 
     11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
     11.4 CONTRACT RESEARCH ORGANIZATIONS 
12 LEUKAPHERESIS MARKET, BY REGION, 2021-2028 (USD MILLION) 
     12.1 INTRODUCTION 
     12.2 NORTH AMERICA 
             12.2.1 RECESSION IMPACT
             12.2.2 US 
             12.2.3 CANADA
     12.3 EUROPE 
             12.3.1 RECESSION IMPACT
             12.3.3 GERMANY 
             12.3.4 UK
             12.3.5 FRANCE
             12.3.6 SPAIN
             12.3.7 ITALY
             12.3.8 REST OF EUROPE
     12.4 ASIA PACIFIC 
             12.4.1 RECESSION IMPACT
             12.4.2 JAPAN
             12.4.3 CHINA
             12.4.4 INDIA
             12.4.5 AUSTRALIA
             12.4.6 SOUTH KOREA
             12.4.7 REST OF ASIA PACIFIC
     12.5 LATIN AMERICA 
             12.5.1 RECESSION IMPACT
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 RECESSION IMPACT
13 COMPETITIVE LANDSCAPE 
     13.1 OVERVIEW 
     13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
     13.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022) 
     13.4 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS 
     13.5 LEUKAPHERESIS MARKET SHARE ANALYSIS (2022) 
     13.6 LEUKOPAKS MARKET SHARE ANALYSIS (2022) 
     13.7 COMPANY EVALUATION MATRIX (2022) (LEUKAPHERESIS PRODUCTS MARKET) 
             13.7.1 STARS 
             13.7.2 EMERGING LEADERS
             13.7.3 PERVASIVE PLAYERS
             13.7.5 PARTICIPANTS
             13.7.6 COMPANY FOOTPRINT
     13.8 START-UPS/SME EVALUATION MATRIX (2022) (LEUKAPHERESIS PRODUCTS MARKET) 
             13.8.1 PROGRESSIVE COMPANIES
             13.8.2 RESPONSIVE COMPANIES
             13.8.3 DYNAMIC COMPANIES
             13.8.4 STARTING BLOCKS
             13.8.5 COMPETITIVE BENCHMARKING
     13.9 COMPANY EVALUATION MATRIX (2022) (LEUKOPAKS MARKET) 
             13.9.1 STARS 
             13.9.2 EMERGING LEADERS
             13.9.3 PERVASIVE PLAYERS
             13.9.5 PARTICIPANTS
             13.9.6 COMPETITIVE BENCHMARKING
     13.1 COMPETITIVE SITUATION AND TRENDS 
             13.10.1 PRODUCT LAUNCHES
             13.10.3 DEALS
             13.10.4 EXPANSIONS
14 COMPANY PROFILES 
     14.1 KEY PLAYERS 
             14.1.1 ASAHI KASEI MEDICAL CO. LTD. (JAPAN)
             14.1.2 FRESENIUS SE & CO. KGAA (GERMANY)
             14.1.3 HAEMONETICS CORPORATION (US)
             14.1.4 TERUMO BCT, INC. (US)
             14.1.5 MACOPHARMA SA (FRANCE)
             14.1.6 MILTENYI BIOTEC (GERMANY)
             14.1.7 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD. (CHINA)
             14.1.8 MEDICA S.P.A (ITALY)
             14.1.9 PURIBLOOD MEDICAL CO. LTD. (TAIWAN)
     14.2 OTHER PLAYERS (LEUKAPHERESIS MARKET) 
             14.2.1 BEIJING ZKSK TECHNOLOGY CO. LTD. (CHINA)
             14.2.2 MALLINCKRODT PHARMACEUTICALS 
             14.2.3 NIKKISO CO., LTD. (JAPAN)
             14.2.4 PALL CORPORATION
     14.3 KEY PLAYERS (LEUKOPAKS MARKET) 
             14.3.1 ALLCELLS, LLC (US)
             14.3.2 STEMEXPRESS, LLC. (US)
             14.3.3 CHARLES RIVER LABORATORIES (US)
             14.3.4 LONZA GROUP AG (SWITZERLAND)
             14.3.5 CALTAG MEDSYSTEMS LIMITED (UK)
             14.3.6 ZENBIO (US)
     14.4 OTHER PLAYERS (LEUKOPAKS MARKET) 
             14.4.1 PRECISION FOR MEDICINE (US)
             14.4.2 BIOIVT (US)
             14.4.3 INTELLIGENT TISSUE GROUP (US)
             14.4.4 TRINA BIOREACTIVES AG (SWITZERLAND)
             14.4.5 ACCEGEN
             14.4.6 FIRST CHOICE BIO LLC
15 APPENDIX 
     15.1 INSIGHTS OF INDUSTRY EXPERTS 
     15.2 DISCUSSION GUIDE 
     15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.4 AVAILABLE CUSTOMIZATION 
     15.5 RELATED REPORTS 
     15.6 AUTHOR DETAILS  
*The segmentation of the study can be updated during the course of the study based on primary insights and secondary research
*The list of companies mentioned above is indicative only and might change during the course of the study.
*Details on key financials might not be captured in case of unlisted companies.